US Patent No: 6,479,510
Number of patents in Portfolio can not be more than 2000
Quinuclidine-substituted aryl compounds for treatment of disease
Stats
-
Nov 12, 2002
Issued date -
Aug 17, 2001
filing date -
09/932,598
serial no -
Expired
status
Importance
Loading Importance Indicators...
Abstract
The invention provides compounds of Formula I: ##STR1## These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which .alpha.7 is known to be involved.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 4,593,034 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | 23 | 1984 | |
| 4,605,652 Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes | 42 | 1985 | |
| 4,870,181 Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides | 6 | 1985 | |
| 4,717,563 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs | 11 | 1986 | |
| 4,908,370 Anxiolytic-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides | 11 | 1987 | |
| 4,863,919 Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes | 10 | 1988 | |
| 5,206,246 Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | 11 | 1991 | |
|
|
|||
| 5,070,095 Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents | 9 | 1990 | |
| 5,084,460 Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides | 10 | 1990 | |
| 5,236,931 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol | 10 | 1992 | |
| 5,273,972 [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates | 27 | 1992 | |
|
|
|||
| 4,803,199 Pharmaceutically useful heterocyclic and carbocyclic acid esters and amides of alkylene bridged piperidines | 26 | 1987 | |
| 5,039,680 New use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | 59 | 1990 | |
| 5,561,149 Use of certain imidazol carbazols in treating stress-related manic-depressive disorders | 59 | 1995 | |
|
|
|||
| 4,721,720 Method of treating emesis, anxiety and/or IBS | 39 | 1986 | |
| 4,798,829 1-Azabicyclo[3,2,2]nonane derivatives having 5-HT receptor antagonist activity | 32 | 1986 | |
|
|
|||
| 4,657,911 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function | 27 | 1983 | |
| 5,017,580 Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | 12 | 1989 | |
|
|
|||
| 5,741,819 Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors | 25 | 1995 | |
|
|
|||
| 5,025,022 Method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides | 11 | 1989 | |
|
|
|||
| 4,877,794 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia | 5 | 1988 | |
|
|
|||
| 5,106,843 Heterocyclic compounds useful as 5-HT.sub.3 antagonists | 14 | 1989 | |
|
|
|||
| 4,820,715 Anti-emetic quinuclidinyl benzamides | 11 | 1987 | |
|
|
|||
| 5,057,519 5-HT.sub.3 antagonists: use in reducing opiate tolerance | 15 | 1990 | |
|
|
|||
| 5,290,938 Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide | 3 | 1992 | |
|
|
|||
| 5,237,066 Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy | 9 | 1991 | |
|
|
|||
| 5,183,822 Substituted 3,4-annelated benzimidazol-2(1H)-ones | 10 | 1990 | |
|
|
|||
| 4,921,982 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT.sub.3 antagonists | 20 | 1989 | |
|
|
|||
| 5,246,942 Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration | 8 | 1992 | |
|
|
|||
| 5,837,489 Human neuronal nicotinic acetylcholine receptor and cells transformed with same DNA and mRNA encoding an--subunit of | 18 | 1995 | |
|
|
|||
| 5,919,793 Heterocyclic derivatives | 8 | 1995 | |
|
|
|||
| 5,491,148 Isoquinolinone and dihydroisoquinolinone 5-HT.sub.3 receptor antagonists | 25 | 1991 | |
|
|
|||
| 5,977,144 Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines | 33 | 1997 | |
|
|
|||
| 4,835,162 Agonists and antagonists to nicotine as smoking deterents | 64 | 1987 | |
|
|
|||
| 5,723,103 Substituted benzamides and radioligand analogs and methods of use | 6 | 1994 | |
|
|
|||
| 4,877,780 Antiemetic N-substituted benzamides | 13 | 1988 | |
|
|
|||
| 5,175,173 Carboxamides useful as antiemetic or antipsychotic agents | 17 | 1989 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | May 12, 2014 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |